FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Commercial · sales Growing supply to Korean hospitals while running trials at US medical institutions. Also seen: Global approvals · expansion

  • Extended its exclusive Korean distribution agreement with a 2026 volume of 12,000 units. Source
  • Holds US FDA clearance and is running trials at about 30 medical institutions in six US states. Source

Roles often seen at this stageDevice R&D & support · Sales & marketing · Regulatory affairs

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

MEZOO

The maker of the HiCardi wearable patient monitor, sold in Korea with a pharmaceutical partner and being trialled at US medical institutions.

HiCardi

Marketed

Wearable patient monitor that continuously measures ECG and other vital signs; the Korean sales agreement was widened to 12,000 units a year.

Completion reported

Extended its exclusive Korean distribution agreement and set the 2026 contract volume at 12,000 units.

Official role guide

MEZOO careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 메쥬-동아에스티 '하이카디' 국내 독점 판매 계약 연장·확대… 2026년 연간 계약수량 1만2000대 ↗뉴스와이어 · Published 2026-05-08 · Sources checked 2026-11-15 · Original unavailable
  2. 메쥬 코스닥 도전…'하이카디' 앞세워 미국 시장 공략 ↗네이트 뉴스 · Published 2026-03-09 · Sources checked 2026-11-15 · Original unavailable